ArticleResearch square2026
Multiomics Profiling Supports Cathepsin B as a Protective Factor in Cerebral Small Vessel Disease.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
White matter hyperintensities (WMH) are a common brain MRI marker of cerebral small vessel disease and a major risk factor for stroke and dementia, yet the molecular mechanisms governing lesion formation remain incompletely understood. Here, we combined large-scale proteomic and genomic data with tissue- and single-nucleus transcriptomic validation to identify circulating proteins that influence WMH volume and its downstream clinical manifestations. Association and Mendelian Randomization analyses of WMH volume and 2,923 plasma proteins in 52,560 UK Biobank participants identified the lysosomal protease cathepsin B (CTSB) and the mitochondrial enzyme Enoyl-CoA Hydratase Domain Containing 3 (ECHDC3) as the top candidates associated with WMH volume. Single-nucleus RNA sequencing of post-mortem periventricular white matter from 8 individuals (4 with WMH lesions and 4 matched controls) revealed a marked downregulation of CTSB in WMH lesions, predominantly in astrocytes and oligodendrocytes, whereas ECHDC3 expression was unchanged between cases and controls. In the UK Biobank, higher plasma CTSB levels and a cis-pQTL polygenic score each predicted better general cognitive ability, independent of vascular risk factors, whereas ECHDC3 showed no cognitive association. Together, these multimodal analyses across different studies point to CTSB as a lesion-suppressed, cognition-enhancing factor and a plausible therapeutic target for mitigating the effects of WMH and preserving brain health.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.